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Correlation between serum butyrylcholinesterase
activity and serum lipid concentrations in rats treated
with different antagonists of the adrenergic system
Abstract
Background and Purpose: Based on the facts that the blockade of adre-
nergic receptors can alter lipid profile in the serum and that it has been
suggested that butyrylcholinesterase (BuChE) is involved in lipid metabolism,
different adrenergic blocking agents were administered to rats to modify
lipid concentrations in serum. The activity of BuChE was examined under
such conditions and correlations with serum lipids were investigated. The
purpose of this study was to evaluate the effects of different adrenergic
antagonists on BuChE activity and to investigate the correlation between
BuChE activity and serum lipids.
Materials andMethods: Six groups of male Fischer 344 rats (9 animals/
group) were treated orally with adrenergic antagonists (mixed in com-
mercial diet) during 6 weeks: oxprenolol, atenolol, doxazosin, oxprenolol
and doxazosin, atenolol and doxazosin, and guanethidine. A control group
(9 rats) received only commercial diet. BuChE activity in serum was
determined with kinetic color test using butyrylthiocholine as a substrate.
Concentrations of serum lipids (total cholesterol, triglycerides and HDL
cholesterol) were determined by enzymatic colorimetric tests. Data were
analyzed by Kruskal-Wallis test and Spearman’s correlation coefficient.
Results:The results revealed that oxprenolol and doxazosin (given alone
or in combination with atenolol or oxprenolol) increased (>30 %) BuChE
activity. BuChE activity correlated with different serum lipids, and correla-
tion depended on the type of adrenergic blockade.
Conclusion: Although the examined adrenergic antagonists did not
influence serum lipid concentrations, the increase of BuChE activity and
correlation with serum lipid concentrations suggested that the increase of
this enzyme’s activity might be the first sign of altered lipid metabolism.
INTRODUCTION
Butyrylcholinesterase (BuChE, pseudocholinesterase, EC 3.1.1.8) isa serum esterase which is synthesized primarily in the liver (1) and
released into plasma immediately following its synthesis. This enzyme
is also found in the small intestine, smooth muscle, adipose tissue,
brain and other tissues, but it is not known whether this enzyme
originates only from blood, or whether it can be synthesized in those
tissues as well. The true physiological function of BuChE has not yet been
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(AChE, EC 3.1.1.7) in the nervous system, with an im-
portant role in the regulation of slow impulse conduction
in the nervous system, and that it is included in the
hydrolysis of ingested esters from plant sources (2, 3). On
the other hand, the clinical importance of BuChE is well
known. It hydrolyzes muscle relaxant succinylcholine
and local anesthetics like procaine and tetracaine hydro-
chloride (4, 5). When plasma BuChE activity is low, as
the result of inadequate hepatic synthesis or in the case of
abnormal genetic variants, the metabolism of succinylcho-
line is reduced resulting in the increase in the duration of
muscular relaxation and prolonged respiratory paralysis.
Because BuChE activity in plasma can reflect the rate of
its formation in hepatocytes, quantitative determination
of the catalytic activity of BuChE in serum and plasma
may be used as a biomarker to identify liver disorders. A
decrease in BuChE activity in plasma is an indicator of
pesticide poisoning.
Results of some investigators have shown that BuChE
is probably involved in lipid metabolism. Clitherow et al
suggested that BuChE might hydrolyze butyrylcholine
possibly formed during fatty acid metabolism (6). Bal-
lantyne et al. showed that BuChE occurred in the seba-
ceus gland and adipose tissue and suggested that BuChE
took part in lipid metabolism (7, 8). An increased serum
BuChE activity is usually observed in conditions associ-
ated with altered lipid metabolism such as hyperlipo-
proteinemia, obesity and diabetes (3, 9–17). Thus, in-
creased activity of BuChE was found when triglyceride
(TG), very low density lipoprotein (VLDL) or low den-
sity lipoprotein (LDL) concentrations were increased in
animal models of diabetes and obesity (9–11). Increased
activity can be found in patients with diabetes (13, 14),
obesity and hyperlipoproteinemia (15, 16, 17) as well.
It is well known that a and b adrenergic receptor an-
tagonists modify the metabolism of carbohydrates and
lipids, when they are used in patients (18–28) for treat-
ment of hypertension. The reported data about the effect
of adrenergic receptor antagonists on lipid metabolism
are conflicting and different. While selective b1 and non-
selective b1,2 adrenergic receptor antagonists mostly in-
crease TG and/or LDL cholesterol level and reduce HDL
cholesterol (20–25, 28), those that act as a1 adrenergic re-
ceptor antagonists can increase HDL cholesterol (HDL-C)
and decrease total cholesterol (TC) or TG concentra-
tions (18–21, 25–28). The sympathetic system is known
to have several of important effects on metabolic pro-
cesses in adipose tissue. So it has been suggested that
catecholamines are of major importance for the regula-
tion of lipolysis in adipose tissue. In human fat cells, both
b1 and b2 adrenergic receptors are known to stimulate
cAMP production and lipolysis in vitro and in vivo (29,
30). b3 adrenergic receptors are highly expressed in ro-
dent white and brown adipose tissue and are relatively
specific for this tissue. Selective agonists of b3 adrenergic
receptors elicit a marked lipolytic and thermogenic re-
sponse in rodents (29, 30). According to literature data,
the level of expression and the contribution of the b3 re-
ceptor to catecholamine-induced lipolysis in human
subcutaneous adipocytes seem to be limited (31). Anti-
lipolytic effect of catecholamines is exerted through the
stimulation of a2 adrenergic receptors on fat cells (29,
32). It was suggested that catecholamines have a higher
affinity for a2 than for b adrenergic receptor, and that
they are responsible for a adrenergic pathways in the
control of lipolysis in humans (33).
Propranolol, a nonselective b adrenergic receptor an-
tagonist, was shown to inhibit BuChE activity in vitro
(34, 35), but also in vivo in rats (brain tissue) (35). In
contrast, the results of our investigations showed that the
nonselective b adrenergic receptor antagonist oxprenolol
significantly increased BuChE activity in rats of both
sexes when given for a long period of 6–12 weeks (36, 37).
As serum TG or TC concentrations were altered in these
experiments, it was concluded that the increase of enzyme
activity was due to the altered lipid metabolism caused by
oxprenolol rather than its direct effect on the enzyme.
Different adrenergic receptor antagonists are com-
monly used for treatment of cardiovascular diseases, so it
was of interest to assess whether other adrenergic anta-
gonists also influenced serum BuChE activity. It was also
of interest to examine if there was any correlation be-
tween serum BuChE activity and serum lipid concentra-
tions (TG, TC and HDL-C). For this purpose, adrener-
gic antagonists with different site of action were used in
the experiment: non-selective b1 and b2 adrenergic receptor
antagonist oxprenolol, selective b1 adrenergic receptor
antagonist atenolol, a1 adrenergic receptor antagonist




Test substances oxprenolol hydrochloride (CAS 6452-
-71-7), atenolol (CAS 29122-68-7), and doxazosin mesylate
(CAS 77883-43-3) were donated by PLIVA d.d. (Zagreb,
Croatia). Guanethidine monosulfate (CAS 645-43-2) was
obtained from Sigma.
Animals
Male Fischer 344 rats (PLIVA Research Institute), 3
months old, with average weight of 270 g were used in
the experiment. The animals were housed (3 rats/cage)
in makrolon cages (dimension 425x266x180 mm). The
cages were located in rooms under controlled conditions
(12h light: 12h dark, temperature 22 °C ±3 and relative
humidity 55% ± 10). Before the treatment started, the
animals were randomized according to their body weights.
Housing, handling and treatment of animals were con-
ducted on the basis of the current guide and directive for
laboratory animals (38, 39).
Study design and dosage
The animals were divided in seven groups (9 rats/
group). Six groups were treated with tested substances
for 6 weeks as follows: 1). group with oxprenolol; 2). with
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atenolol; 3). with doxazosin; 4).with oxprenolol and dox-
azosin; 5). with atenolol and doxazosin; and 6). group
with guanethidine. The substances were mixed in com-
mercial diet for laboratory mice and rats (manufactured
by PLIVA Veterina i agrar) and offered to animals ad
libitum. The calculated average doses at the end of the
treatment period were 9.6, 5.5, 1.9, and 2 mg/kg/day for
oxprenolol, atenolol, doxazosin and guanethidine, res-
pectively. The doses of antagonists were at least 2 times
higher than maximum recommended human doses
(mg/kg body weight). The seventh group of animals
belonged to the control group and the rats were fed ad
libitum only with commercial diet for laboratory animals
(manufactured by PLIVA Veterina i agrar). The animals
from all groups had free access to tap water (bottles). At
the end of the treatment period the animals were anes-
thetized with overdose of barbiturate thiopental and blood
samples were obtained from carotid artery. The serum
was stored at –20 °C until analyzed.
Measurement of BuChE activity in
serum
BuChE activity (U/L) in serum was determined on
an automatic biochemical analyzer using a commercial
kit with butyrylthiocholine as a substrate (OLYMPUS
System Reagent Cholinesterase).
Measurement of serum lipid
concentrations
Concentrations of TG and TC in serum were deter-
mined on automatic biochemical analyzer using enzy-
matic colorimetric tests and commercial kits OLYMPUS
System Reagent 500 for triglycerides and cholesterol.
The concentration of HDL-C was determined by enzy-
matic colorometric tests in the supernatant (HERBOS
DIJAGNOSTIKA) after the precipitation of VLDL and
LDL with polyethylene glycol (QUANTOLIP HDL,
IMMUNO AG). The concentrations of serum lipids
were expressed in mmol/L.
Statistical analysis
Kruskal-Wallis test was used to compare BuChE activity
between groups. Data are shown as median, quartiles
(25% and 75%), minimum and maximum.
Correlations between BuChE activity and the con-
centrations of TG, TC or HDL-C were derived using
Spearman’s correlation.
Post-hoc test was used for group comparison. The
results were considered significant with p<0.05.
The percentage (%) of change in enzyme activity or
lipid concentrations vs control group was based on the
difference between calculated mean values.
RESULTS
Effects on serum BuChE activity
Box and whisker plot of the BuChE activities in rat
serum in 7 groups after 6 weeks of treatment are pre-
sented in Figure 1. The administration of oxprenolol at
the dose of 9.6 mg/kg/day induced the increase in serum
BuChE activity of 39.8 % compared to the control group.
Atenolol administered at the dose of 5.5 mg/kg/day in-
duced the increase of 27.9% compared to the control
group. A statistically significant increase in BuChE ac-
tivity (p<0.01) was observed when doxazosin was given
at the dose of 1.9 mg/kg/day. Doxazosin increased the
enzyme activity by 51.6% compared to the control group.
Concurrent administration of oxprenolol and doxazosin
induced the increase in BuChE activity of 44.4% com-
pared to the control group. When atenolol and doxazosin
were given concurrently, the increase in BuChE activity
of 34.2% (vs control) was observed. The measured BuChE
activity in guanethidine-treated group (2 mg/kg/day) was
similar to those of the control group. The increase was
about 10.2%.
Effects on serum lipid concentration
No significant alteration in any of the examined lipid
concentrations was observed in the experiment. The high-
est obtained change (either increase or decrease) was a
decrease in TG by 19 % vs control in the doxazosin-
treated group.
Correlation between BuChE activity and
serum lipids
The correlations of serum BuChE activity with serum
lipid concentrations (TC, TG or HDL-C) in rats are
presented in Table 1. Positive correlations between serum
BuChE activity and TC (p<0.01) or HDL-C (p<0.05)
was found in the oxprenolol treated group. In the atenolol
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Figure 1. Box and whisker plot of the BuChE activity (U/L) in male
Fischer 344 rat serum in 7 groups after 6 weeks treatment: 9.6 mg
oxprenolol/kg/day (O), 5.5 mg atenolol/kg/day (A), 1.9 mg doxazo-
sin/kg/day (D), 9.6 mg oxprenolol and 1.9 mg doxazosin/kg/day (OD),
5.5 mg atenolol and 1.9 mg doxazosin/kg/day (AD), 2 mg guanethi-
dine/kg/day (G) and control group (C). Statistical significance
(**P<0.01) showed differences between the control group and the
treated group. The small box is median, bigger box is the upper and
lower quartiles (25 %-75 %), and the vertical bars are the full range of
values in the data minimum and maximum (Kruskal-Wallis test).
treated group, positive correlation was found (p<0.05)
between BuChE activity and TG concentration. No sta-
tistically significant correlation was observed between
BuChE activity and any of the examined lipid concen-
trations in the doxazosin treated group. Concurrent ad-
ministration of oxprenolol and doxazosin revealed ne-
gative correlation (p<0.05) between BuChE activity and
TG concentration. When atenolol and doxazosin were
given concurrently, no statistically significant correlation
was observed between BuChE activity and examined
lipids. Guanethidine treatment did not induce a sta-
tistically significant correlation between BuChE activity
and the serum lipids examined. When all groups were
evaluated together irrespective of treatment, positive cor-
relations were obtained between BuChE activity and TC
or HDL-C (p<0.01), but negative correlation was ob-
tained between enzyme activity and TG (p<0.05).
DISCUSSION
The present results are in agreement with our earlier
results obtained in rats of both sexes when we found that
chronic oxprenolol treatment causes an increase in BuChE
activity (36, 37) (Figure 1). Although the increase in
BuChE activity was not significant, as it was in our
earlier experiments, the increase was higher than 35%
(39.8% vs control). We suggest that the increase was not
significant because of the lower dose of oxprenolol used
in the current study. Actually, the calculated dose levels
which we used in our earlier experiments were higher
(15 and 30 mg/kg/day) in comparison with the dose level
in the current experiment (9.6 mg/kg/day) (see Material
and Methods). Despite this difference in the significance
of BuChE activity obtained in our present and earlier
results, we considered that oxprenolol had a potential to
increase the activity of BuChE. Although chronic ox-
prenolol treatment did not alter significantly any of the
serum lipid concentrations, a positive correlation between
BuChE activity and serum TC and HDL-C was obtained
(Table 1). The positive influence of oxprenolol on TC and
HDL-C concentrations in present results is congruent
with the results of our earlier experiments (36, 40) when
we found significantly higher concentrations of TC (36)
and HDL-C (40) after chronic oxprenolol treatment in
comparison with the control group. On the other hand,
our experiments with oxprenolol and glibenclamide sho-
wed a significant decrease in HDL-C after oxprenolol
treatment (37). We suppose that the influence of oxpre-
nolol on TC and HDL can vary and that it probably
depends on some factors, such as specific cholesterol
transport in the rat which is qualitatively various from
humans (41), or dose level of oxprenolol used.
Our present results showed that oxprenolol did not al-
ter serum TG concentration, which is opposite to our
earlier results (37). In our opinion, these opposite results
are probably due to two factors. The first and most im-
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TABLE 1
Correlation of serum BuChE activity with serum lipid concentrations (total cholesterol, triglycerides or HDL cholesterol)
in male Fischer 344 rats (number of samples (N) = 8–9/group) after 6 weeks of treatment with different adrenergic
antagonists (oxprenolol, atenolol, doxazosin, oxprenolol and doxazosin, atenolol and doxazosin, or guanethidine)
and in the control group. Spearman’s correlation coefficient (r) was used to identify the relation between BuChE and
the serum lipids and significance probabilities were calculated (*P<0.05; **P<0.01). Calculations were performed
for each group separately and for all the groups together (irrespective of treatment).
Group (N) Total cholesterol Triglycerides HDL cholesterol
Oxprenolol BuChE r 0.842(**) –0.184 0.703(*)
(N=9) P 0.004 0.635 0.035
Atenolol r 0.428 0.669(*) 0.218
(N=9) P 0.251 0.049 0.574
Doxazosin r 0.452 –0.144 0.358
(N=9) P 0.222 0.711 0.344
Oxprenolol & Doxazosin r 0.150 –0.669(*) 0.639
(N=9) P 0.700 0.049 0.064
Atenolol & Doxazosin r 0.517 –0.395 0.346
(N=9) P 0.154 0.293 0.362
Guanethidine r –0.112 0.072 0.228
(N=9) P 0.774 0.854 0.555
Control group r 0.506 0.429 0.467
(N=8) P 0.201 0.289 0.243
All group together r 0.377(**) –0.288(*) 0.357(**)
(N=62) P 0.002 0.023 0.004
portant factor is the lower dose level of oxprenolol and
shorter treatment in comparison to a higher dose level and
longer treatment (12 weeks) in our earlier experiments.
The second factor may be a higher sensitivity of a2-antili-
polytic adrenoreceptors in adipose tissue and a1 adrener-
gic receptor in rat hepatocytes (42) for catecholamine,
which became visible in the present experiment due to un-
identified reason. It is known that the effect of adrenergic
receptor antagonists on blood lipid level diffeers. Our re-
sults also showed that the influence of oxprenolol on se-
rum lipids is dissimilar. Although either TC or TG was
increased, the activity of BuChE was always increased.
Because of these different observations in serum lipid con-
centrations, further studies in this area are indicated.
Our results showed that atenolol did not cause a signi-
ficant increase in BuChE activity. Although the increase of
enzyme activity was below 30%, the coefficient of cor-
relation was positive with serum TG, suggesting that the
higher dose of atenolol or its longer administration would
probably increase the TG concentration together with the
increase in BuChE activity. This is congruent with the
results of Gaafar et al. who showed that atenolol at a dose
of 9 mg/kg/day caused an increase in serum TG in healthy
male rats after 30 days of treatment (43). At this moment
the full explanation of the mechanism of the TG modify-
ing effects of atenolol remains unavailable since different
factors can be responsible.
In humans, doxazosin as an a1 adrenergic receptor
antagonist usually decreases TG or TC and increases
HDL-C (21, 44). We would expect a decrease in BuChE
activity after doxazosin treatment since positive correla-
tion between BuChE and TG, or BuChE and TC, was
found (13, 14, 45). Surprisingly, 6 weeks of treatment
with doxazosin increased BuChE activity, and this in-
crease was statistically significant. Although it did not
significantly change the serum lipid profile, doxazosin
caused a decrease in serum TG by 19% vs control, and
that was the highest obtained change (either increase or
decrease) in the lipid concentration observed in this ex-
periment. Recent data in experiments by á- and â-ad-
renoreceptor agonists in isolated rat hepatocytes also
showed that â adrenergic receptors are involved in
VLDL secretion, i.e. â adrenergic receptor agonist iso-
proterenol caused a significant inhibition of triglyceride
secretion (42). Their results were very useful in explain-
ing the results of our experiments. In our experiments,
we suggest that the decrease in TG concentration after
doxazosin-treatment is a consequence of noradrenaline
agonistic action on those adrenoreceptors which are re-
sponsible for antilipolytic effect of catecholamines (i.e â
adrenergic receptors in hepatocytes and a2 adrenergic re-
ceptors in adipose tissue). We do not know the reason why
BuChE activity and TG concentration relation was not
proportional.
As expected, guanethidine, which is an adrenergic
neuron-blocking agent, did not have any influence on
BuChE activity or serum lipid concentrations, and we
did not find any significant correlation between BuChE
activity and lipids. All the results were similar to those of
the control group. Guanethidine is know to cause »phar-
macological sympathectomy« and disappearance of
noradrenaline in blood. We suggested that the low level
of adrenaline that is secreted from adrenal medulla is
sufficient for its permissive metabolic agonistic action on
all free adrenergic receptors. Due to this reason the val-
ues of enzyme activity and serum lipids obtained in rats
on guanethidine were similar to those obtained in the
control group. Thus »pharmacological sympathectomy«
is a possible explaination why the results after guane-
thidine treatment were similar to those obtained in the
control group, but this is only a hypothesis and it should
be further investigated.
A significant negative correlation between BuChE
and TG was observed after treatment with doxazosin
and oxprenolol combination, when b1,2 and a1 adrener-
gic receptors were blocked, but not in the case of b1 and
a1 adrenergic receptor blockade (atenolol and doxazo-
sin) (Table 1). The increase in BuChE activity was above
30% after both treatments, i.e. an increase in enzyme
activity by 44.4% was observed after concurrent admini-
stration of oxprenolol and doxazosin and by 34.2% after
administration of atenolol and doxazosin (Figure 1).
According to these results, concurrent uses of doxazosin
with oxprenolol or atenolol have no additional effect on
serum BuChE and serum lipid concentration.
It is known that different adrenergic receptor antago-
nists alter serum lipid concentrations differently (21).
Our present results showed that they also had a different
effect on BuChE activity. Although adrenergic receptors
antagonists which we used in our experiments did not
significantly alter serum lipid concentration, the increase
in BuChE activity and demonstrable correlation with se-
rum lipids suggested that the increase in enzyme activity
might be the first sign of altered lipid metabolism. The
results of the coefficient of correlation obtained from all
groups together (Table 1), irrespective of the treatment,
suggested that there was a positive correlation between
the BuChE activity and TC and HDL-C in rat serum.
Contrary to that, there was a negative correlation be-
tween BuChE activity and TG concentration.
CONCLUSION
Our results obtained in rats showed that some adre-
nergic receptor antagonists (doxazosin and oxprenolol)
which we used in our experiments can increase serum
BuChE activity. Although oxprenolol, atenolol and dox-
azosin, given alone or in combination, did not signifi-
cantly influence serum lipid concentration, the increase
in BuChE activity and the obtained correlation with
certain serum lipids suggest that the increase in enzyme
activity might be the first sign of altered lipid meta-
bolism. We suppose that all these effects of adrenergic
receptor antagonists, i.e. BuChE activity, serum lipid
concentration and correlation between BuChE and li-
pids, depend on the type of adrenergic receptor and its
antagonist. Our results also suggest that the measure-
ment of BuChE activity during treatment with adrenergic
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receptor antagonists is of clinical significance. A decrease
or increase in BuChE activity can alter the metabolism of
other drugs and, as a consequence, change the drug
safety and efficacy (mainly when activity is decreased).
Iatrogenic modification of BuChE can also influence
diagnosis of certain conditions during which the enzyme
activity is either decreased or increased.
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